Non-alcoholic fatty liver disease (NAFLD) is a rapidly growing global health problem and represents the hepatic manifestation of metabolic syndrome. The pathogenesis of NAFLD is complex and involves insulin resistance, lipid accumulation, oxidative stress, chronic inflammation, and endothelial dysfunction. Selectins, a family of cell adhesion molecules, play a crucial role in leukocyte–endothelium interactions and inflammatory cell recruitment. Increasing evidence suggests that selectins contribute to endothelial activation and inflammatory processes in metabolic disorders, including NAFLD. This study aimed to investigate the role of P-, E-, and L-selectins in the formation and progression of NAFLD. The findings demonstrate that altered circulating levels of selectins are closely associated with the severity of hepatic steatosis and inflammatory activity, highlighting their potential as biomarkers and therapeutic targets in NAFLD.